<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03022825</url>
  </required_header>
  <id_info>
    <org_study_id>CA-ALT-803-01-16</org_study_id>
    <nct_id>NCT03022825</nct_id>
  </id_info>
  <brief_title>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</brief_title>
  <official_title>QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altor BioScience</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altor BioScience</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II, open-label, single-arm, multicenter study of intravesical BCG plus
      ALT-803 in patients with BCG unresponsive high grade non-muscle invasive bladder cancer
      (NMIBC). All patients treated in the study will receive via a urinary catheter in the
      bladder, BCG plus ALT-803 weekly for 6 consecutive weeks (initial induction treatment
      period). After the first disease assessment, eligible patients will receive either a 3-week
      maintenance course or a 6-week re-induction course (second treatment period) at Month 3.
      Eligible patients will continue to receive maintenance treatment in the third treatment
      period at Months 6, 9, 12, and 18. The study duration is 24 months.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2017</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 Months</time_frame>
    <description>Assess incidence of complete response of CIS patients at any time.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>6 months</time_frame>
    <description>Assess durability of complete response at 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>9 months</time_frame>
    <description>Assess durability of complete response at 9 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>12 months</time_frame>
    <description>Assess durability of complete response at 12 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>18 months</time_frame>
    <description>Assess durability of complete response at 18 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response</measure>
    <time_frame>24 months</time_frame>
    <description>Assess durability of complete response at 24 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time from first treatment to death resulting from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to cystectomy</measure>
    <time_frame>24 months</time_frame>
    <description>Assess time from first treatment to cystectomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>24 months</time_frame>
    <description>Assess incidence of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL)</measure>
    <time_frame>24 months</time_frame>
    <description>Compare changes in QOL scores from baseline</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>BCG+ALT-803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-803</intervention_name>
    <description>BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.</description>
    <arm_group_label>BCG+ALT-803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG</intervention_name>
    <description>BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive maintenance treatment in the third treatment period at Months 6, 9, 12, and 18.</description>
    <arm_group_label>BCG+ALT-803</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients 18 years of age or older

          -  Histologic confirmation of non-muscle invasive bladder cancer of the transitional cell
             carcinoma high-grade subtype

          -  Histologically confirmed presence of BCG-unresponsive CIS (with or without Ta or T1
             disease) or histologically confirmed presence of BCG-unresponsive high-grade Ta or T1
             disease.

          -  Absence of resectable disease after transurethral resection (TURBT) procedures
             (residual carcinoma in situ (CIS) acceptable; patients with T1 tumors must undergo
             repeat resection and biopsy [inclusive of muscularis propria] if initial biopsy did
             not include muscularis propria). Patients with high-grade Ta and/or T1 disease should
             have complete resection before study treatment.

          -  BCG-unresponsive disease as defined as: (a) Persistent or recurrent CIS (+/- recurrent
             Ta/T1 disease) within 12 months of receiving adequate BCG (at least five of six doses
             doses of an initial induction course plus either at least two of three doses of
             maintenance therapy or at least two of six doses of a second induction course); or (b)
             Recurrent high-grade Ta/T1 disease within 6 months of completion of adequate BCG (at
             least five of six doses of an initial induction course plus either at least two of
             three doses of maintenance therapy or at least two of six doses of a second induction
             course); or (c) T1 high-grade disease at the first evaluation following an induction
             BCG course alone (at least five of six doses of an initial induction course).

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          -  Voluntary written informed consent and HIPAA authorization and agree to comply with
             all protocol-specified procedures and follow-up evaluations

        Exclusion Criteria:

          -  Recurrence of BCG unresponsive Ta/T1 disease &gt; 6 months after last BCG instillation or
             BCG unresponsive CIS &gt; 12 months after last BCG instillation.

          -  Life expectancy &lt;2 years

          -  Any of the following clinical laboratory values at the time of enrollment: (1)
             Absolute neutrophil count (ANC) &lt;800/µL or (2) Platelets &lt; 50,000/µL

          -  Liver function abnormalities as indicated by ongoing hepatic enzyme elevation (AST or
             ALT) &gt;2 times upper limit of normal (ULN)

          -  Renal insufficiency as indicated by a creatinine level &gt;3 times ULN

          -  Evidence of muscle-invasive or regional and/or distant metastatic bladder cancer, or
             high grade urothelial carcinoma in the prostate or upper urinary tract

          -  Symptomatic congestive heart failure (CHF), New York Heart Association (NYHA) Class
             III or IV heart failure or other clinical signs of severe cardiac dysfunction

          -  Severe/unstable angina pectoris, or myocardial infarction within 6 months prior to
             study entry

          -  History or evidence of uncontrollable central nervous system (CNS) disease

          -  Active systemic infection requiring parenteral antibiotic therapy. All prior
             infections must have resolved following optimal therapy

          -  Concurrent febrile illness, active urinary tract infection, active tuberculosis, a
             history of hypotension or anaphylactic reactions

          -  Ongoing chronic systemic steroid therapy required (&gt;10 mg oral prednisone daily or
             equivalent)

          -  Women who are pregnant or nursing. Female patients of childbearing potential must have
             a negative pregnancy test and must adhere to using a medically acceptable method of
             birth control prior to screening and agree to continue its use during the study and
             for 30 days after the last dose of study drug, or be surgically sterilized (e.g.,
             hysterectomy or tubal ligation). Women of childbearing potential are defined as any
             female who has experienced menarche and who is NOT permanently sterile or
             postmenopausal. Postmenopausal is defined as 12 consecutive months with no menses
             without an alternative medical cause. Males must agree to use barrier methods of birth
             control while on study and for 90 days post last dose of study drug.

          -  Patients currently receiving investigational or commercial anti-cancer agents or
             anti-cancer therapies other than BCG, ALT-803 and supportive care therapies.

          -  Concurrent use of other investigational agents

          -  Other illness or condition, including laboratory abnormalities, which in the opinion
             of the Investigator would exclude the patient from participating in this study. This
             includes, but is not limited to, serious medical conditions or psychiatric illness
             likely to interfere with participation in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karim Chamie, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amy Rock, PhD</last_name>
    <phone>954-443-8600</phone>
    <email>amyrock@altorbioscience.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Liza Hernandez, BS</last_name>
    <phone>954-443-8600</phone>
    <email>lizahernandez@altorbioscience.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Alaska Clinical Research Center</name>
      <address>
        <city>Anchorage</city>
        <state>Alaska</state>
        <zip>99503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Adams, RMA</last_name>
      <phone>907-276-1455</phone>
      <email>LAdams@akmed.com</email>
    </contact>
    <investigator>
      <last_name>William R Clark, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Coast Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90004</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Brigitte Romoya</last_name>
      <phone>310-673-3333</phone>
      <email>bhanna@westcoasturology.com</email>
    </contact>
    <investigator>
      <last_name>Ernest Agatstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Urology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ankush Sachdeva</last_name>
      <phone>310-794-3421</phone>
      <email>ASachdeva@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Karim Chamie, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amirali H Salmasi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Sherman Oaks</city>
        <state>California</state>
        <zip>91411</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey M Gomez</last_name>
      <phone>310-602-5018</phone>
      <email>stacey.gomez@skyuro.com</email>
    </contact>
    <investigator>
      <last_name>Richard D David, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Skyline Urology</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stacey M Gomez</last_name>
      <phone>310-602-5018</phone>
      <email>stacey.gomez@skyuro.com</email>
    </contact>
    <investigator>
      <last_name>Fredrick N Wolk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urology Associates, PC</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenden Neeper</last_name>
      <phone>303-733-8848</phone>
      <phone_ext>1262</phone_ext>
      <email>L.Neeper@uradenver.com</email>
    </contact>
    <investigator>
      <last_name>Barrett Cowan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Eastern Connecticut Hematology and Oncology Associates</name>
      <address>
        <city>Norwich</city>
        <state>Connecticut</state>
        <zip>06360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Wilcox, RN</last_name>
      <phone>860-886-8362</phone>
      <email>nwilcox@echoct.com</email>
    </contact>
    <investigator>
      <last_name>Dennis E Slater, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rody Barakat</last_name>
      <phone>305-243-2177</phone>
      <email>rxb773@med.miami.edu</email>
    </contact>
    <investigator>
      <last_name>Mark L Gonzalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dwight D. Eisenhower Army Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elsa Salazar</last_name>
      <phone>706-787-5811</phone>
      <email>elsa.c.salazar2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Aaron Brothers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96814</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Hui</last_name>
      <phone>808-564-5801</phone>
      <email>ehui@cc.hawaii.edu</email>
    </contact>
    <investigator>
      <last_name>Charles J Rosser, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tripler Army Medical Center</name>
      <address>
        <city>Kailua</city>
        <state>Hawaii</state>
        <zip>96734</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nina Bermudez</last_name>
      <phone>808-433-2972</phone>
      <email>nina.o.bermudez.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Joseph Sterbis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benas Jakubauskas</last_name>
      <phone>773-702-3080</phone>
      <email>bjakubauskas@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Gary Steinberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ochsner Clinic Foundation</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Margaret Variano</last_name>
      <phone>504-842-2961</phone>
      <email>margaret.variano@ochsner.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Canter, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tamara Dimovski</last_name>
      <phone>313-576-9771</phone>
      <email>dimovskt@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Michael L Cher, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bethany Marlette</last_name>
      <phone>612-626-6661</phone>
      <email>marle025@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Joseph Zabell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Insitute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Colleen Borsuk</last_name>
      <phone>716-845-1657</phone>
      <email>Colleen.borsuk@roswellpark.org</email>
    </contact>
    <investigator>
      <last_name>Khurshid Guru, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winthrop University Hospital Department of Urology</name>
      <address>
        <city>Garden City</city>
        <state>New York</state>
        <zip>11530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amanda Le Sueur, PhD</last_name>
      <phone>516-535-4184</phone>
      <email>alesueur@NYUWinthrop.org</email>
    </contact>
    <investigator>
      <last_name>Aaron E Katz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Manhattan Medical Research</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmela Graci-Pipitone, RN</last_name>
      <phone>212-480-3333</phone>
      <email>cgpipitone@manhattanmedicalresearch.com</email>
    </contact>
    <investigator>
      <last_name>Jed Kaminetsky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Medical Group of the Hudson Valley</name>
      <address>
        <city>Poughkeepsie</city>
        <state>New York</state>
        <zip>12601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Crespi, LPN</last_name>
      <phone>845-437-5010</phone>
      <email>mailto:lcrespi@premiermedicalhv.com</email>
    </contact>
    <investigator>
      <last_name>Evan Goldfischer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinical Research Solutions</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Kalapis</last_name>
      <phone>440-305-8150</phone>
      <email>JKalapis@crssites.com</email>
    </contact>
    <investigator>
      <last_name>Michael T Barkoukis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Toledo Clinic</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Martinez</last_name>
      <phone>419-479-5605</phone>
      <email>jmartinez@toledoclinic.com</email>
    </contact>
    <investigator>
      <last_name>Rex Mowat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Riza Fabreo</last_name>
      <phone>405-271-8777</phone>
      <email>Riza-Fabreo@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Sanjay Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katherine Burns</last_name>
      <phone>215-503-3754</phone>
      <email>Katherine.Burns@jefferson.edu</email>
    </contact>
    <investigator>
      <last_name>Edouard Trabulsi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pamela Steele, RN</last_name>
      <phone>615-343-2120</phone>
      <email>pamela.steele@vanderbilt.edu</email>
    </contact>
    <investigator>
      <last_name>Sam Chang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Army Medical Center</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melinda Abamukong</last_name>
      <phone>915-742-3432</phone>
      <email>MAbamukong@genevausa.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Morilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Madigan Army Medical Center</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98431</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Drew Thomas</last_name>
      <phone>253-968-2300</phone>
      <email>drew.m.thomas2.ctr@mail.mil</email>
    </contact>
    <investigator>
      <last_name>Timothy C Brand, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2017</study_first_submitted>
  <study_first_submitted_qc>January 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 18, 2017</study_first_posted>
  <last_update_submitted>March 23, 2018</last_update_submitted>
  <last_update_submitted_qc>March 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BCG</keyword>
  <keyword>bladder cancer</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>interleukin-15</keyword>
  <keyword>intravesical</keyword>
  <keyword>non-muscle invasive</keyword>
  <keyword>NMIBC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

